Please assess the completion status of the following clinical trial:

Trial Title: GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Able to provide informed consent~* Able and willing to comply with study procedures~* Able and willing to utilize an approved form of pregnancy prevention for women of child bearing potential through to the end of treatment~Exclusion Criteria:~* Know allergy to quinine, quinidine, or mefloquine~* Confirmed prior positive test for SARS-CoV-2~* Treatment within the past 2 weeks with chloroquine, hydroxychloroquine, or remdesivir~* Pregnancy or documentation of pregnancy by pre-treatment urine test or breast feeding or plans to become pregnant during the course of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- GLS-1200 (Type: EXPERIMENTAL): 1 mL of GLS-1200 per nostril, TID
- 0.9 %Saline (Type: PLACEBO_COMPARATOR): 1 mL of 0.9% Saline per nostril, TID

Based on this trial design, predict the completion outcome and termination type (if applicable).